Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial

Atea Pharmaceuticals (AVIR) announced completion of enrollment of more than 880 treatment-naive patients in the C-BEYOND Phase 3 trial evaluating the fixed-dose combination, FDC, regimen of bemnifosbuvir and ruzasvir compared to the FDC regimen of sofosbuvir and velpatasvir for the treatment of hepatitis C virus, HCV. C-BEYOND is being conducted at approximately 120 clinical trial sites in the US and Canada. Phase 3 topline results are expected mid-year 2026.